RTOG Foundation Studies 3509 and 3510/RADCOMP
Status Date: February 29, 2016 | Status: Open to Accrual
Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium
Justin E. Bekelman, MD
To assess the effectiveness of proton vs. photon therapy in reducing major cardiovascular events (MCE), defined as atherosclerotic coronary heart disease or other heart disease death, myocardial infarction, coronary revascularization, or hospitalization for major cardiovascular event (heart failure, valvular disease, arrhythmia, or unstable anginaor unstable angina or other major cardiovascular event).
Females or males diagnosed with pathologically (histologically) proven invasive mammary carcinoma (ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy/local excision with any type of axillary or internal mammary node chain surgery or sampling.
The University of Pennsylvania is the sponsor of this study. More information on this trial is available on ClinicalTrials.gov or by emailing RTOG-Membership@acr.org.